Sun Pharma's Billion-Dollar Bet

Sun Pharma’s US innovative medicines just crossed $1 billion. Unloxcyt is the newest piece of that puzzle. It is an oncology immunotherapy, first of its kind in its class, now commercially available in the US.But is it a platform asset or a niche product? And what does it actually signal about Indian pharma’s innovation transition?That’s what this episode is about. Listen in. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com